Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + nivolumab + doxorubicin + vinblastine + dacarbazine + rituximab
- Development stage
- Unknown
- Lead developer
- New York Medical College
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Bv-NAVD-R is an experimental chemo-immunotherapy combination regimen being evaluated for the treatment of children, adolescents, and young adults with newly diagnosed mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL). Developed by New York Medical College and studied in the Phase 2 RADICAL trial (NCT05253495), the regimen consists of the anti-CD30 antibody-drug conjugate brentuximab vedotin, the PD-1 checkpoint inhibitor nivolumab, and the anti-CD20 monoclonal antibody rituximab, combined with a chemotherapy backbone of doxorubicin (Adriamycin), vinblastine, and dacarbazine. The regimen is designed to leverage targeted immunotherapy to maintain high cure rates while reducing the intensity of conventional chemotherapy and radiation, thereby minimizing long-term toxicities such as cardiotoxicity and secondary malignancies in young patients.
- Other names
- Bv-NAVD-R regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)PDCD1 (Programmed cell death protein 1 receptor)TOP2A (DNA topoisomerase II)CD30 (CD30 antigen)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on brentuximab vedotin + nivolumab + doxorubicin + vinblastine + dacarbazine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + nivolumab + doxorubicin + vinblastine + dacarbazine + rituximab.